Truist Financial has increased its price target for Incyte (NASDAQ: INCY) to $105.00, indicating a potential 1.73% upside. Incyte secured regulatory approval for its drug Minjuvi® in Japan, ...
Apogee Therapeutics, Inc. (NASDAQ:APGE) surged du...
Today's market saw significant declines, particul...
Paychex is projected to report robust Q4 earnings, driven by significant revenue and EPS growth. Growth is primarily fueled by the company's management solutions segment and strategic pricing
Cerebras Systems Inc. (NASDAQ: CBRS): AI-Compute Growth Meets Valuation Debate Cerebras Systems Inc. operates in the fast-growing AI-compute market, where it competes with larger and more diversified
Outdoor Holding Company (NASDAQ: POWW) Q4 Earnings: Revenue Beat, Narrower Losses, and Cost Discipline Outdoor Holding Company reported quarterly revenue of $13.89 million, beating analyst expectatio
Spruce Biosciences (NASDAQ: SPRB) is developing a late-stage therapy (TA-ERT) for Sanfilippo Syndrome Type B, a rare pediatric neurodegenerative disorder with no current FDA-approved treatments.
Investment firm Citigroup maintains a "Neutral" rating for Rivian (NASDAQ: RIVN) with a price target of $15.38, reflecting current market conditions and its electric vehicle (EV) market outlook.
Regenxbio Inc. (NASDAQ: RGNX) Surges on Positive Analyst Outlook and FDA Alignment for Gene Therapy Analyst Brian Skorney of Robert W. Baird raised the price target for Regenxbio Inc. to $32.00, indi
